What is Hirudin?
Hirudin is a 65-amino acid polypeptide originally isolated from the salivary glands of the medicinal leech (Hirudo medicinalis) that functions as a direct thrombin inhibitor and is now available in recombinant forms (lepirudin and desirudin) for clinical use as an anticoagulant. 1
Mechanism of Action
Hirudin works as a direct thrombin inhibitor with intrinsic anticoagulant activity—meaning it does not require plasma cofactors like antithrombin to exert its effect, unlike heparin 1. The drug inhibits thrombin through a bivalent mechanism:
- The globular amino-terminal domain binds directly to thrombin's active site
- The anionic carboxy-terminal tail binds to exosite 1 on thrombin (the substrate-binding site)
- Forms high-affinity 1:1 stoichiometric complexes with thrombin that are essentially irreversible 1
This dual binding makes hirudin the most potent natural thrombin inhibitor known, capable of inhibiting both fluid-phase and clot-bound thrombin 2, 3.
Clinical Formulations and Approved Uses
Two recombinant forms are currently approved 1:
Lepirudin
- Licensed for: Treatment of thrombosis complicating heparin-induced thrombocytopenia (HIT)
- Route: Intravenous
- Dosing: 0.15 mg/kg/h continuous infusion with or without 0.4 mg/kg initial bolus
- Monitoring: aPTT with target ratio of 1.5-2.5 times control
Desirudin
- Licensed for: Postoperative thromboprophylaxis in patients undergoing elective hip arthroplasty
- Route: Subcutaneous
- Dosing: 15 mg twice daily
- Monitoring: Not required
Pharmacokinetics
Critical renal considerations:
- Half-life: 60 minutes after IV injection; 120 minutes after subcutaneous injection 1
- Clearance: Exclusively via the kidneys 1, 4
- Renal impairment: Drug accumulates rapidly when CrCl < 60 mL/min
- Contraindication: Absolute contraindication in patients with renal failure 1
Dose adjustment is mandatory when creatinine clearance falls below 60 mL/min to prevent dangerous drug accumulation 1.
Important Clinical Caveats
Antibody Formation
Up to 40% of patients develop antibodies against hirudin during lepirudin treatment 1. While most antibodies have no clinical impact, some can:
- Prolong the plasma half-life of lepirudin, causing drug accumulation
- Trigger anaphylaxis upon re-exposure 1
Therefore, an alternative anticoagulant should be used in patients with HIT who have previously received hirudin 1.
Bleeding Risk
In a retrospective analysis of 181 HIT patients treated with lepirudin:
- 20.4% suffered major hemorrhage
- 13.8% experienced thrombotic events
- Mean treatment duration was 7.7 days 1
No Reversal Agent
Unlike heparin (reversed by protamine), there is no specific reversal agent for hirudin 5. This makes bleeding complications particularly challenging to manage.
Comparison to Other Anticoagulants
Hirudin differs fundamentally from indirect anticoagulants (heparin, fondaparinux) because it:
- Does not require antithrombin as a cofactor 1
- Inhibits clot-bound thrombin, which heparin cannot access 2
- Provides more predictable anticoagulation than heparin 6
- Has exclusive specificity for thrombin 4, 7
However, hirudin is not as effective as heparin in blocking thrombin generation, though it is more effective at inhibiting existing thrombin activity 6.
Alternative Direct Thrombin Inhibitors
Bivalirudin, a synthetic hirudin analog, offers advantages over hirudin 1:
- Shorter half-life (25 minutes)
- Only 20% renal excretion (safer in renal impairment)
- Not immunogenic (unlike hirudin)
- Reversible thrombin binding (thrombin cleaves the drug after binding)
Argatroban provides another alternative with hepatic metabolism, making it particularly useful in HIT patients with severe renal impairment 1.